Pfizer Hopes To Convince FDA With Event-Free Survival Data For Mylotarg

US agency usually uses endpoint of overall survival to assess acute myeloid leukemia drugs; Mylotarg initially garnered accelerated approval in 2000, but was withdrawn when a confirmatory trial failed to show a clinical benefit. Now it's back before the Oncologic Drugs Advisory Committee.